.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Colorcon
Moodys
US Department of Justice
Mallinckrodt
Chinese Patent Office
Healthtrust
Chubb
Federal Trade Commission
Teva

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090211

« Back to Dashboard

NDA 090211 describes BACITRACIN, which is a drug marketed by Akorn, Fresenius Kabi Usa, Pfizer, Pharmacia And Upjohn, Sagent Strides, Xellia Pharms Aps, Lilly, Perrigo Co Tennessee, Pharmaderm, Pharmafair, Combe, Naska, Apothekernes, Paddock Llc, Bausch And Lomb, and Altana, and is included in twenty-three NDAs. It is available from nine suppliers. Additional details are available on the BACITRACIN profile page.

The generic ingredient in BACITRACIN is bacitracin; hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate. There are twenty-seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the bacitracin; hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate profile page.

Summary for 090211

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 090211

Suppliers and Packaging for NDA: 090211

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BACITRACIN bacitracin INJECTABLE;INJECTION 090211 ANDA Sagent Pharmaceuticals 25021-116 25021-116-30 1 VIAL in 1 CARTON (25021-116-30) > 10 mL in 1 VIAL
BACITRACIN bacitracin INJECTABLE;INJECTION 090211 ANDA Sagent Pharmaceuticals 25021-116 25021-116-31 10 VIAL in 1 CARTON (25021-116-31) > 10 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength50,000 UNITS/VIAL
Approval Date:May 11, 2010TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Novartis
Medtronic
Fish and Richardson
US Department of Justice
Cantor Fitzgerald
Boehringer Ingelheim
AstraZeneca
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot